Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Pulmonary Arterial Hypertension
Interventions: Cicletanine, Cicletanine Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 39
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Adult ADHD
Interventions: AZD1446, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Los Alamitos, California • Fort Myers, Florida • New York, New York + 3 more

Conditions: Healthy
Interventions: PF-04958242, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Kidney Disease
Interventions: Zemplar Capsule; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 16
States / cities: San Diego, California • Washington D.C., District of Columbia • Fort Meyers, Florida + 12 more

Conditions: Kidney Transplant; Complications, Metabolic Acidosis
Interventions: Sodium Bicarbonate, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Malaria
Interventions: AQ-13, Chloroquine (CQ) Treatment; Drug
Lead sponsor: Tulane University Health Sciences Center; Other
Eligibility: 21 Years to 45 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Heavy Menstrual Bleeding, Uterine Fibroid
Interventions: Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 89
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more

Conditions: Erectile Dysfunction
Interventions: Placebo, One POMx capsule daily, 2 POMx Capsules; Drug
Lead sponsor: POM Wonderful LLC; Industry
Eligibility: 21 Years to 70 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Huntsville, Alabama

Conditions: Major Depressive Disorder, Healthy Volunteer
Interventions: Basimglurant, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions: Vancomycin, Neomycin and MTT capsules, Placebo capsules; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Heart Failure, HFpEF, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions: Placebo (matching), Beta-blockers; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pleasanton, California

Conditions: MPOX
Interventions: Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 44
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more

Conditions: Menopause, Cognitive Disturbances
Interventions: atomoxetine, placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions: Solriamfetol Oral Tablet [Sunosi], Placebo; Drug
Lead sponsor: Rochester Center for Behavioral Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester Hills, Michigan

Conditions: Irritable Bowel Syndrome
Interventions: Fecal microbiota transplantation capsules, Placebo capsules; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 19 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Hamden, Connecticut • New York, New York • The Bronx, New York

Conditions: Multiple Sclerosis
Interventions: Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more

Conditions: Pain, Postoperative
Interventions: Single shot interscalene nerve block, Continuous interscalene nerve block, Local Infiltration Analgesia (LIA); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Systemic Lupus Erythematosus
Interventions: Hydroxychloroquine, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 55 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 12
States / cities: Los Angeles, California • San Diego, California • Atlanta, Georgia + 5 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 109
States / cities: Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more

Conditions: Diabetes Mellitus Type 1
Interventions: ORMD-0801 Capsules, Placebo; Biological · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Tustin, California

Conditions: Schizophrenia
Interventions: ITI-007, Placebo, Risperidone; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: Little Rock, Arkansas • Garden Grove, California • Atlanta, Georgia + 5 more

Conditions: Diabetic Nephropathy
Interventions: CTP-499; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Tardive Dyskinesia
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 21
States / cities: Costa Mesa, California • Fountain Valley, California • Oceanside, California + 17 more

Conditions: Primary Biliary Cirrhosis
Interventions: GKT137831, Placebo oral capsule; Drug
Lead sponsor: Calliditas Therapeutics AB; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Phoenix, Arizona • Sacramento, California • Ventura, California + 17 more

Search by objective public record fields.

Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)

Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis

Bicarbonate Administration in Kidney Transplant Recipients

Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

POMx In the Treatment of Erectile Dysfunction

A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

Study of Tecovirimat for Human Mpox Virus

Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women

A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Analgesic Efficacy of Interscalene Nerve Block Versus Local Infiltration Analgesia Following Total Shoulder Arthroplasty

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics

Study of a Novel Antipsychotic ITI-007 in Schizophrenia

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.